Search research articles
Contact Us
Filters
Showing results (1-10 of 87) with videos related to
Page
of 9
Sort By:
Hematology/Oncology Clinics of North America
|
October 17, 2003
Chronic myeloid leukemia
Richard T Silver
Current Hematology Reports
|
May 4, 2005
Treatment of polycythemia vera with recombinant interferon alpha (rIFNalpha) or imatinib mesylate
Richard T Silver
Cancer
|
June 29, 2006
Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha
Richard T Silver
The Oncologist
|
April 1, 2011
Predictive value of in vitro mutation data to guide second-generation tyrosine kinase inhibitor selection: ready for prime time?
Richard T Silver
Best Practice & Research. Clinical Haematology
|
December 5, 2009
The blast phase of chronic myeloid leukaemia
Richard T Silver
Seminars in Thrombosis and Hemostasis
|
July 1, 2006
Treatment of polycythemia vera
Richard T Silver
Current Hematologic Malignancy Reports
|
April 29, 2010
Update on the treatment of polycythemia vera with recombinant interferon alfa or imatinib mesylate
Richard T Silver
Blood
|
October 18, 2014
Life, genes, and death in Ph- MPNs
Richard T Silver
Clinical Lymphoma, Myeloma & Leukemia
|
October 30, 2010
Uncommon or delayed adverse events associated with imatinib treatment for chronic myeloid leukemia
Rishard Salie, Richard T Silver
Annals of Hematology
|
March 28, 2015
Management of chronic myeloid leukemia in blast crisis
S Saußele, Richard T Silver
Page
of 9
Search research articles
Search
Showing results (1-10 of 87) with videos related to
Sort By:
Page
of 9
Hematology/Oncology Clinics of North America
|
October 17, 2003
Chronic myeloid leukemia
Richard T Silver
Current Hematology Reports
|
May 4, 2005
Treatment of polycythemia vera with recombinant interferon alpha (rIFNalpha) or imatinib mesylate
Richard T Silver
Cancer
|
June 29, 2006
Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha
Richard T Silver
The Oncologist
|
April 1, 2011
Predictive value of in vitro mutation data to guide second-generation tyrosine kinase inhibitor selection: ready for prime time?
Richard T Silver
Best Practice & Research. Clinical Haematology
|
December 5, 2009
The blast phase of chronic myeloid leukaemia
Richard T Silver
Seminars in Thrombosis and Hemostasis
|
July 1, 2006
Treatment of polycythemia vera
Richard T Silver
Current Hematologic Malignancy Reports
|
April 29, 2010
Update on the treatment of polycythemia vera with recombinant interferon alfa or imatinib mesylate
Richard T Silver
Blood
|
October 18, 2014
Life, genes, and death in Ph- MPNs
Richard T Silver
Clinical Lymphoma, Myeloma & Leukemia
|
October 30, 2010
Uncommon or delayed adverse events associated with imatinib treatment for chronic myeloid leukemia
Rishard Salie, Richard T Silver
Annals of Hematology
|
March 28, 2015
Management of chronic myeloid leukemia in blast crisis
S Saußele, Richard T Silver
Page
of 9